PEGylated Proteins Market Size, Share, By Type (Consumables, and Services), By Protein (Colony-stimulating factor, Interferons, Erythropoietin, Recombinant factor VII, and Other), By Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder, and Others), By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutes), and By Region - Trends, Analysis and Forecast till 2034

PEGylated Proteins Market is experiencing significant growth, driven by increasing demand for enhanced biologic drugs with improved stability, solubility and extended half-life. Advances in biotechnology, increasing incidence of chronic diseases and high approval of PEGylated drugs also support this market. However, high cost of goods and regulatory challenges may hinder market expansion.

• In 2023, PEGylated Proteins market was estimated to be worth USD 1.34 Billion.
• By 2034, the target market is expected to grow to USD 5.67 Billion.
• Target market is expanding at a CAGR of 11.5%

Key Takeaways:

• North America held the largest share of the market in 2024.
• Asia Pacific is projected to be the fastest-growing market in the coming years.
• By Application, the Cancer is expected to account for the largest share of the PEGylated Proteins market in upcoming years.

                             To Know More, Request Free Sample Report

Key Drivers of Target Market:

Increasing Disease Burden

The worldwide diseases such as cancer, rheumatoid arthritis, chronic kidney disease, hepatitis, and hemophilia are ever-increasing. PEGylated proteins have been used for all these diseases with better pharmaceutical characteristics.

• For Instance, according to Springer Nature Limited, in October 2020, Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea and other research institutes conducted study on the incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer from March 2015 to February 2020. As a result, the study denotes the superiority, clinical features and treatment of aortitis induced through PEGylated filgrastim in sufferers with breast most cancers. A general of 2068 consecutive patients who underwent neoadjuvant/adjuvant chemotherapy with PEGylated filgrastim for breast most cancers were enrolled.

Growing Biopharmaceutical Industry

• The biopharmaceutical industry is growing daily. Advanced technologies are being adopted, and an increasing demand for biologicals has led to growth in the market for PEGylated proteins, which is a critical component of the biologics industry.

Restrains:

Immunogenic Reactions

PEGylation decreases the protein's immunogenicity. PEGylated proteins can, despite efforts to minimize immunogenicity, biased the immune response in certain patients and cause some adverse events. This risk of immunogenicity may present an impediment for its wider adoption especially among the sensitive patient population.

• Counterbalance Statements: The new generation of PEGylation techniques is designed to further reduce immune responses, there has been a growth of techniques in the area of specific site PEGylation. These methods are helpful in attaching PEG (polyethylene glycol) on specific positions of the protein to obtain minimal immunogenic responses without losing the effectiveness of therapy. By utilizing these PEGylation targeting techniques, the developers of these treatments can limit the immunogenicity risks and provide safer treatment options which implemented growth in the market.

Opportunities:

Innovation for Biosimilar PEGylated

This can be attributed to improve demands for complex biopharmaceuticals and targeted therapy. The PEGylation process improves the stability, solubility, and half-life of therapeutic proteins, thus enabling a more effective drug with reduced immunogenicity. This has led to enhanced uptake in various fields such as oncology, autoimmune disorders, and chronic diseases.

• For instance, in August 2024, Tanvex BioPharma USA, Inc.announced that it has received FDA approval for its NYPOZI (filgrastim-txid), the first biosimilar to Neupogen, to be used in the treatment of chemotherapy-induced neutropenia in cancer patients. Also, the FDA has approved Tanvex's Biologics License Application for TX-05, a HER2-positive breast and gastric cancer biosimilar. It represents Tanvex's contribution to developing available, high-quality biologic therapies.

The market is segmented based on Type, Protein Type, Application, End-User and Region

Type Insights:

On the basis of Protein Type PEGylated Proteins market is segmented into Consumables and services.

Protein Type Insights:

On the basis of Protein Type PEGylated Proteins market is segmented into Colony Stimulating Factors, Interferons, Erythropoietin, Recombinant Factor VIII, Others. Erythropoietin segment is expected to account largest revenue share in the forecast period.

• For Instance, In August 2023, Coherus BioSciences had an encouraging update on the PEGylated CSF drug product, Udenyca, which is a biosimilar of Neulasta. Coherus gained FDA approval on the on-body injector device (OBI); the administration of PEGylated filgrastim made easy by this, thereby improving the comfort and convenience of patients and increasing the adoption of the product.

Application Insights:

The PEGylated Proteins market by application is segmented into Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder, Others.

End-User Insights:

The PEGylated Proteins market by end-user is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes. Pharmaceutical & Biotechnology Companies are the in most leading developing sector, which involves drug developments.

• For Instance, in August 2024, The FDA approved Amgen's new PEGylated protein drug to treat a rare form of anemia. PEGylation of the drug results in an extended half-life, which minimizes dosing frequency and yields better compliance and quality of life for the patient.

Regional Insights

North America: The PEGylated proteins market is dominated by North America, especially the U.S., due to its advanced healthcare infrastructure, significant investment in biotechnology, and large patient pool that requires treatment with biologic therapies. The region also has a more favorable regulatory environment and research initiatives, further encouraging market growth.

Asia Pacific: The PEGylated proteins market in the Asia Pacific region is experiencing rapid growth, mainly due to growing health care investments and higher incidence of chronic diseases. Biopharmaceutical manufacturing capabilities are also on an upswing here, and it makes countries such as China, Japan, and India prominent production and consumption units.  

PEGylated Proteins Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels, analyzing industry trends and opportunities across sub-segments from 2024 to 2034. It segments the market by Type, Protein Type, Application, End-User, and Region.

Segmentation:

By Type:

• Consumables
• Services

By Protein Type:

• Colony Stimulating Factors
• Interferons
• Erythropoietin
• Recombinant Factor VIII
• Others

By Application:

• Cancer
• Autoimmune Disease
• Hepatitis
• Multiple Sclerosis
• Hemophilia
• Gastrointestinal Disorder
• Others

By End-User:

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic and Research Institutes

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the PEGylated Proteins Market include Amgen Inc., Pfizer Inc., Merck Millipore, Thermo Fisher Scientific, Inc., NOF Corporation, JenKem Technology USA, Inc., Creative PEGworks, Celares GmbH, Quanta BioDesign, Ltd. Biomatrik, Inc., Iris Biotech GmbH, Laysan Bio, Ltd. 

                     To Access More Companies, Download Free Sample PDF

• In August 2024, the EMA approved a new formulation of PEGylated interferon for the treatment of chronic Hepatitis C, under the name Approval of PEGylated Interferon for Hepatitis C. The new formulation is designed with improved pharmacokinetics, allowing it to be dosed bi-weekly instead of weekly, thus making the product more tolerable for the patient.

Analyst View:

PEGylation improves the stability, half-life, and effectiveness of protein-based drugs in treating chronic diseases like cancer and rheumatoid arthritis. Overall, the PEGylated Proteins market has a promising outlook with increasing applications in the healthcare sector.

More Related Reports
Erythropoietin Drugs Market
Cancer Diagnostics Market
Pancreatic cancer treatment market
Multi-Cancer Early Detection Market
Hemophilia Treatment Market

• Amgen Inc.,
• Pfizer Inc.
• Merck Millipore
• Thermo Fisher Scientific, Inc.
• NOF Corporation
• JenKem Technology USA, Inc.
• Creative PEGworks
• Celares GmbH
• Quanta BioDesign, Ltd
• Biomatrik, Inc.
• Iris Biotech GmbH
• Laysan Bio, Ltd.